These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36468954)

  • 21. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
    Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
    Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
    [No Abstract]   [Full Text] [Related]  

  • 22. Proceedings Report of the Fifth Symposium on Hidradenitis Suppurativa Advances (SHSA) 2020.
    Schneider C; Adelman M; Almuhanna N; Sakya S; Delorme I; Hamzavi I; Kirby JS
    J Drugs Dermatol; 2021 Aug; 20(8):868-873. PubMed ID: 34397198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy.
    Vural S; Gündoğdu M; Akay BN; Boyvat A; Erdem C; Koçyiğit P; Bostancı S; Sanli H; Kundakci N
    Dermatol Ther; 2019 Sep; 32(5):e13003. PubMed ID: 31237104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on Hormonal Therapy in Hidradenitis Suppurativa.
    Karagaiah P; Daveluy S; Ortega-Loayza A; Gulliver W; Szepietowski J; Grabbe S; Goldust M
    J Drugs Dermatol; 2023 Apr; 22(4):369-374. PubMed ID: 37026880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hidradenitis Suppurativa: Review of the Pathogenesis and Treatment.
    Kurayev A; Ashkar H; Saraiya A; Gottlieb AB
    J Drugs Dermatol; 2016 Aug; 15(8):1017-22. PubMed ID: 27538005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
    Peterson GC; Preston A; Frieder J; Wang X; Paek SY
    Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
    Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
    Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.
    Giuffrida R; Cannavò SP; Coppola M; Guarneri C
    Curr Pharm Biotechnol; 2021; 22(1):59-72. PubMed ID: 32368973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic.
    Kearney N; Hughes R; Kirby B
    Clin Exp Dermatol; 2023 Jul; 48(7):790-792. PubMed ID: 37017188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development.
    Westerkam L; Sayed C
    J Drugs Dermatol; 2023 Oct; 22(10):1021-1026. PubMed ID: 37801538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review.
    Kashetsky N; Mufti A; Alabdulrazzaq S; Lytvyn Y; Sachdeva M; Rahat A; Yeung J
    J Cutan Med Surg; 2022; 26(1):79-86. PubMed ID: 34365863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
    Prussick L; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Abdat R; Alomran A; Zancanaro P; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    Br J Dermatol; 2019 Sep; 181(3):609-611. PubMed ID: 30801662
    [No Abstract]   [Full Text] [Related]  

  • 35. Hidradenitis Suppurativa Found Associated With Cytokine Storm.
    Yang B; Temiz LA; Duran MA; Miller AC; Adjei S; Tyring SK; Wu T
    J Drugs Dermatol; 2024 May; 23(5):e134-e136. PubMed ID: 38709689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
    Holcomb ZE; Porter ML; Kimball AB
    Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hidradenitis suppurativa in surgeons' practice: Prevalence and treatment approach according to the Hurley stage in Latvia.
    Balcere A; Upeniece I; Snipe K; Jezupovs A
    Dermatol Ther; 2021 Jan; 34(1):e14687. PubMed ID: 33331018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
    van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
    Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
    Gottlieb A; Natsis NE; Kerdel F; Forman S; Gonzalez E; Jimenez G; Hernandez L; Kaffenberger J; Guido G; Lucas K; Montes D; Gold M; Babcock C; Simard J
    J Invest Dermatol; 2020 Aug; 140(8):1538-1545.e2. PubMed ID: 32004568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P; Akoglu G; Dalkıran CD; Caliskan E
    Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.